These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 1737543)

  • 1. Natural course of remission in IDDM during 1st yr after diagnosis.
    Martin S; Pawlowski B; Greulich B; Ziegler AG; Mandrup-Poulsen T; Mahon J
    Diabetes Care; 1992 Jan; 15(1):66-74. PubMed ID: 1737543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial Group.
    Diabetes; 1988 Nov; 37(11):1574-82. PubMed ID: 2903105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of predictive value of islet cell antibodies, insulin antibodies, and HLA-DR phenotype for remission in cyclosporin-treated IDDM patients. The Canadian-European Randomized Control Trial Group.
    Mandrup-Poulsen T; Mølvig J; Andersen HU; Helqvist S; Spinas GA; Munck M
    Diabetes; 1990 Feb; 39(2):204-10. PubMed ID: 2227128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seven years of remission in a type I diabetic patient.
    Koivisto VA; Leirisalo-Repo M; Ebeling P; Tuominen JA; Knip M; Turunen U; Mandrup-Poulsen T; Pelkonen R
    Diabetes Care; 1993 Jul; 16(7):990-5. PubMed ID: 8359107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypersensitivity to insulin during remissions in cyclosporin-treated IDDM patients.
    Burcelin RG; Eddouks M; Beylot M; Normand S; Boitard C; Feutren G; Landais P; Riou JP; Girard JR; Bach JF
    Diabetes Care; 1993 Jun; 16(6):881-8. PubMed ID: 8325202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homogeneity in pattern of decline of beta-cell function in IDDM. Prospective study of 204 consecutive cases followed for 7.4 yr.
    Snorgaard O; Lassen LH; Binder C
    Diabetes Care; 1992 Aug; 15(8):1009-13. PubMed ID: 1505301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients.
    Gottsäter A; Landin-Olsson M; Fernlund P; Lernmark A; Sundkvist G
    Diabetes Care; 1993 Jun; 16(6):902-10. PubMed ID: 8325204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remission in IDDM: prospective study of basal C-peptide and insulin dose in 268 consecutive patients.
    Agner T; Damm P; Binder C
    Diabetes Care; 1987; 10(2):164-9. PubMed ID: 3556104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group.
    J Clin Endocrinol Metab; 1987 Jul; 65(1):30-6. PubMed ID: 2884229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenetic and nutritional profile in insulin-using youth-onset diabetics in Korea.
    Huh KB; Lee HC; Kim HM; Cho YW; Kim YL; Lee KW; Lee EJ; Lim SK; Kim DH; Yoon JW
    Diabetes Res Clin Pract; 1992 Apr; 16(1):63-70. PubMed ID: 1576933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble CD8 antigen, stimulated C-peptide and islet cell antibodies are predictors of insulin requirement in newly diagnosed patients with unclassifiable diabetes.
    Di Bonito P; De Bellis A; Capaldo B; Turco S; Corigliano G; Pace E; Bizzarro A
    Acta Diabetol; 1996 Sep; 33(3):220-4. PubMed ID: 8904929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors predicting residual beta-cell function in the first year after diagnosis of childhood type 1 diabetes.
    Couper JJ; Hudson I; Werther GA; Warne GL; Court JM; Harrison LC
    Diabetes Res Clin Pract; 1991 Jan; 11(1):9-16. PubMed ID: 2019237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutamic acid decarboxylase (GAD65) autoantibodies in prediction of beta-cell function and remission in recent-onset IDDM after cyclosporin treatment. The Canadian-European Randomized Control Trial Group.
    Petersen JS; Dyrberg T; Karlsen AE; Mølvig J; Michelsen B; Nerup J; Mandrup-Poulsen T
    Diabetes; 1994 Nov; 43(11):1291-6. PubMed ID: 7926302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoprotection in spontaneous remission of type 1 diabetes: long-term follow-up results.
    Yilmaz MT; Devrim AS; Biyal F; Satman I; Arioğlu E; Dinççag N; Karsidağ K; Ozden I; Gürel N; Sipahioğlu F
    Diabetes Res Clin Pract; 1993 Feb; 19(2):151-62. PubMed ID: 8472630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenetic and clinical characterization of slowly progressive IDDM.
    Kobayashi T; Tamemoto K; Nakanishi K; Kato N; Okubo M; Kajio H; Sugimoto T; Murase T; Kosaka K
    Diabetes Care; 1993 May; 16(5):780-8. PubMed ID: 8098691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study).
    Pozzilli P; Visalli N; Signore A; Baroni MG; Buzzetti R; Cavallo MG; Boccuni ML; Fava D; Gragnoli C; Andreani D
    Diabetologia; 1995 Jul; 38(7):848-52. PubMed ID: 7556988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results of early cyclosporin therapy in juvenile IDDM.
    De Filippo G; Carel JC; Boitard C; Bougnères PF
    Diabetes; 1996 Jan; 45(1):101-4. PubMed ID: 8522052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of clinical remission in recent-onset IDDM.
    Hramiak IM; Dupre J; Finegood DT
    Diabetes Care; 1993 Jan; 16(1):125-32. PubMed ID: 8422766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin.
    Bougnères PF; Landais P; Boisson C; Carel JC; Frament N; Boitard C; Chaussain JL; Bach JF
    Diabetes; 1990 Oct; 39(10):1264-72. PubMed ID: 2210078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meal-stimulated C-peptide and insulin antibodies in type I diabetic subjects and their nondiabetic siblings characterized by HLA-DR antigens.
    Hoogwerf BJ; Rich SS; Barbosa JJ
    Diabetes; 1985 May; 34(5):440-5. PubMed ID: 3886461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.